Revvity Q2 Revenue Up 4 Percent

Revvity (NYSE:RVTY), a global provider of life sciences and diagnostics tools, released its results for Q2 2025 on July 28, 2025. The company reported GAAP revenue of $720 million, surpassing Wall Street's GAAP estimate of $710.37 million. Adjusted earnings per share (Non-GAAP) landed at $1.18, exceeding analyst projections of $1.14 (non-GAAP) but down from $1.22 in the prior year. These numbers reflect solid performance in a challenging environment, with better-than-expected GAAP top-line and adjusted (non-GAAP) bottom-line results. However, the year-over-year decline in adjusted EPS and compressed operating margins signal persistent cost and profitability pressures. Overall, the quarter showed operational execution and innovation, but raised questions about future margin trends. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Revvity stands at the intersection of life sciences research and clinical diagnostics. It supplies hardware instruments for lab analysis, reagents that are key ingredients for experiments, and software platforms for scientific data management. The company serves pharmaceutical, biotechnology, academic, government, and clinical customers worldwide, enabling drug discovery, medical diagnostics, and genomic workflows.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool